malignant thymoma
Recently Published Documents


TOTAL DOCUMENTS

277
(FIVE YEARS 23)

H-INDEX

29
(FIVE YEARS 1)

2022 ◽  
Author(s):  
Valerio Giacalone
Keyword(s):  

CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A1295
Author(s):  
Mia DeBarros ◽  
Sue Wang ◽  
Grant Fischer ◽  
M. Blair Marshall

Author(s):  
Ching On Luk ◽  
Wai Ting Joyce Lo ◽  
Kitty Yan Kwok ◽  
Moon Ho Leung ◽  
Wing Chi Fong ◽  
...  

Contracturing granulomatous myositis (CGM) is a very rare myopathic syndrome where patients present with slowly progressive muscle pain or weakness affecting mainly proximal muscles together with flexion contractures of the limbs. To date, there have only been several case reports of CGM, which have been reported to occur most commonly in association with sarcoidosis. We report a case of CGM associated with recurrent malignant thymoma and myasthenia gravis (MG). A gentleman with history of treated malignant thymoma presented with new onset proximal muscle weakness and pain that later evolved into contractures that persisted despite treatment with steroids and intravenous immunoglobulin. A malignancy workup revealed recurrence of his malignant thymoma warranting chemotherapy treatment. His contractures only resolved after addition of chemotherapy treatment. He later developed clinical features of MG 1 year after his initial elevation in Anti-acetylcholine (Anti-AChR) antibody levels. We postulate CGM to be a paraneoplastic phenomenon of underlying malignant thymoma. Treatment of thymoma together with immunosuppressive therapies led to clinical improvement of our patient’s CGM. The sole elevation of Anti-AChR levels without the accompanying clinical features does not equate to a MG diagnosis, but should raise the clinician’s vigilance for future development of the condition.


2021 ◽  
Vol 9 ◽  
pp. 2050313X2110559
Author(s):  
Solomon Bendayan ◽  
Roxana Mititelu ◽  
Margaret Elizabeth Redpath ◽  
Robin Billick

Thymoma-associated multiorgan autoimmunity disease can be seen in patients with thymomas and presents with features of graft versus host disease. Here, we report a case of a 52-year-old woman with a complex medical history including malignant thymoma, myasthenia gravis, Good’s syndrome, and T cell large granular lymphocytic leukemia who presented with a diffuse pruritic rash ultimately found to be compatible with a cutaneous presentation of thymoma-associated multiorgan autoimmunity disease. The eruption heralded the recurrence of the malignant thymoma and the rash was ultimately found to be resistant to a multitude of therapies except for oral corticosteroids.


2020 ◽  
Author(s):  
Simran Sawhney ◽  
Ajay Asranna ◽  
Sachin Sureshbabu ◽  
Sudhir Peter ◽  
Sobhana Chindripu ◽  
...  

2020 ◽  
Vol 25 (6) ◽  
pp. 882-885 ◽  
Author(s):  
Ondrej Sorejs ◽  
Milos Pesek ◽  
Jindrich Finek ◽  
Ondrej Fiala

2020 ◽  
Vol 48 (10) ◽  
pp. 030006052096170
Author(s):  
Tianyu Zhang ◽  
Xiao Li ◽  
Ganwei Liu ◽  
Xiuyuan Chen ◽  
Yanguo Liu

A diaphragmatic tumor is usually caused by metastasis from lung cancer, malignant mesothelioma, and malignant thymoma. Endometrial cancer is rarely involved in metastasis to the diaphragm. A right anterior mediastinal tumor was found in a 60-year-old woman who was initially diagnosed with endometrial carcinoma. There was initially no relationship between the right anterior mediastinal tumor and endometrial carcinoma. Radical curative surgery was performed for endometrial carcinoma. The endometrial carcinoma stage was IA. The patient was admitted to the Department of Thoracic Surgery 6 months after the curative surgery. Intraoperative exploration showed a tumor growing in the right diaphragm. Right diaphragmotomy was performed. Immunohistochemistry showed metastasis of endometrial carcinoma to the diaphragm. Endometrial cancer solitary metastasis to the diaphragm is rare. Clinicians should be aware of this possibility. Surgical treatment followed by a pathological examination is the most useful method for determining the diagnosis of a diaphragmatic tumor due to metastasis of endometrial cancer.


2020 ◽  
Vol 91 (10) ◽  
pp. 1076-1084 ◽  
Author(s):  
Sergio Muñiz-Castrillo ◽  
Bastien Joubert ◽  
Mad-Hélénie Elsensohn ◽  
Anne-Laurie Pinto ◽  
Margaux Saint-Martin ◽  
...  

ObjectiveAntibodies against contactin-associated protein-like 2 (CASPR2-Abs) have been described in acquired neuromyotonia, limbic encephalitis (LE) and Morvan syndrome (MoS). However, it is unknown whether these constitute one sole spectrum of diseases with the same immunopathogenesis or three distinct entities with different mechanisms.MethodsA cluster analysis of neurological symptoms was performed in a retrospective cohort of 56 CASPR2-Abs patients. In parallel, immunological features and human leucocyte antigen (HLA) were studied.ResultsCluster analysis distinguished patients with predominant limbic symptoms (n=29/56) from those with peripheral nerve hyperexcitability (PNH; n=27/56). In the limbic-prominent group, limbic features were either isolated (LE/−; 18/56, 32.1%), or combined with extralimbic symptoms (LE/+; 11/56, 19.6%). Those with PNH were separated in one group with severe PNH and extralimbic involvement (PNH/+; 16/56, 28.6%), resembling historical MoS descriptions; and one group with milder and usually isolated PNH (PNH/−; 11/56, 19.6%). LE/− and LE/+ patients shared immunogenetic characteristics demonstrating a homogeneous entity. HLA-DRB1*11:01 was carried more frequently than in healthy controls only by patients with LE (94.1% vs 18.3%; p=1.3×10−10). Patients with LE also had serum titres (median 1:40 960) and rates of cerebrospinal fluid positivity (93.1%) higher than the other groups (p<0.05). Conversely, DRB1*11:01 association was absent in PNH/+ patients, but only they had malignant thymoma (87.5%), serum antibodies against leucine-rich glioma-inactivated 1 protein (66.7%) and against netrin-1 receptor deleted in colorectal carcinoma (53.8%), and myasthenia gravis (50.0%).InterpretationSymptoms’ distribution supports specific clinical phenotypes without overlap between LE and MoS. The distinct immunogenetic characteristics shared by all patients with LE and the particular oncological and autoimmune associations of MoS suggest two very different aetiopathogenesis.


Author(s):  
Timoor Etemad ◽  
Narges Shahbazi ◽  
Khalil Forozannia ◽  
Ali Hosseinsabet

This article is a Letter to the Editor and does not include an Abstract.  


Sign in / Sign up

Export Citation Format

Share Document